SCHEMBL3017803

SCHEMBL3017803

Cc1cc(C)c(S(=O)(=O)C2CCN(c3nc(-c4cccc(C)c4C)cs3)CC2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.44
SMN1; SMN2 Q16637 9/20 0.41
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013518 0.92 AR (0.47) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL2999887 0.91 AR (0.45) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3013877 0.89 SMN1; SMN2 (0.44) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3008894 0.88 AR (0.56) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3010482 0.88 AR (0.48) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3009239 0.87 SMN1; SMN2 (0.45) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3007933 0.86 AR (0.60) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3015281 0.85 AR (0.48) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3009451 0.85 SMN1; SMN2 (0.43) ARSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3009614 0.85 AR (0.40) ARSMN1; SMN2RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.